Van Morris

33PUBLICATIONS
243CO-AUTHORS
Cancer geneticsCancer therapy (excl. chemotherapy and radiation therapy)ChemotherapyPredictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (33)

|May 08, 2026
Reprogramming of Cellular Plasticity via ETS and MYC Core-Regulatory Circuits during Response to MAPK Inhibition in BRAF-Mutant Colorectal Cancer.

|Jan 07, 2026
NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal.

Van K Morris, Kristen K Ciombor, Lianchun Xiao

|Sep 02, 2025
De-escalating local therapies without compromising outcomes: lessons from the COLLISION trial.

Jessica Albuquerque, Noreen S Siddiqi, Van K Morris

|Jul 16, 2025
Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy: INTERCEPT-TT.

Andrew J Pellatt, Alisha Bent, Nicholas Hornstein

|Jul 11, 2025
Phase I Clinical Trial of the Bifunctional EGFR/TGF-β Fusion Protein Ficerafusp Alfa (BCA101) Alone and in Combination with Pembrolizumab for Advanced Solid Tumors.

Alberto Hernando-Calvo, Richard D Carvajal, Paul K Paik

|May 15, 2025
Long-Term Efficacy of Pembrolizumab and the Clinical Utility of ctDNA in Locally Advanced dMMR/MSI-H Solid Tumors.

Michael LaPelusa, Wei Qiao, Bryan Iorgulescu

Pageof 6

Frequent Collaborators

11 joint publications

Scott Kopetz

7 joint publications

Michael Overman

7 joint publications

Cathy Eng

6 joint publications

Arvind N Dasari